Deferred stent implantation in patients with ST segment elevation myocardial infarction with high thrombus burden

Mohamed Abdel-shafy Tabl1*, Khaled Emad El-Rabbat1, Eman Said El-keshk1 and Gamal Mohamed Gharib2

1Department of Cardiology, Benha University, Benha, Egypt
2National Heart Institute, Cairo, Egypt

Received: 10 December, 2018
Accepted: 29 January, 2019
Published: 30 January, 2019

*Corresponding author: Mohamed Abdel-shafy Tabl, Department of Cardiology, Benha University, Benha, Egypt, E-mail: mshafytabl@yahoo.com

Keywords: ST elevation MI; Primary PCI; Deferred stenting

Abstract

Recent guidelines recommend against deferred stenting as a routine strategy in STEMI patients.

Objectives: current study aimed to assess whether deferred stenting strategy in primary PCI might reduce angiographic or in-hospital major adverse cardiac events in comparison to immediate stenting.

Methods: one hundred patients of STEMI with high thrombus burden divided equally into; 50 patients (group 1) treated with immediate stenting and 50 patients (group 2) treated with deferred stenting. Procedural angiographic events were the primary endpoints, while in hospital MACE were designed as secondary endpoints.

Results: patients of deferred stenting group had statistically significant reduction of distal embolization, slow flow and no reflow (P value = 0.016). In contrast, deferred strategy didn’t improve the short term clinical outcomes. Composite of MACEs was statistically significant in the deferred stenting group (20%) versus only (6%) in the immediate stenting group (P value = 0.037).

Conclusion: Deferred stenting in patients with STEMI those with high thrombotic burden improves only the angiographic outcomes but could not improve the short term clinical outcomes in comparison to immediate stenting. Deferred stenting shouldn’t be used as a routine strategy in STEMI patients.

Introduction

Reduced flow to the vascular bed of the infarct–related artery (IRA) is observed in a considerable number of patients treated with primary PCI, especially after stent implantation, even in patients with a normal epicardial flow [1]. Postponed stent implantation (deferred strategy) may potentially limit the risk of distal coronary embolization and may improve the prognosis [2]. In previous studies deferred stenting strategy decreased the rates of angiographic events (distal emboli, no-reflow) with reduction of infarct size [3]. In addition to significant reduction in congestive heart failure, re infarction and cardiac mortality [4]. On the other hand, other randomized trials showed deferred strategy to have unexpected hazards; possible acute coronary re occlusion in the interval between index reperfusion and actual stent implantation in addition to prolonged hospital stay and increased immediate costs [5]. The aim of the current study is to assess whether deferred strategy in primary PCI might reduce angiographic and/or in–hospital clinical major adverse cardiac events (MACE) in comparison to immediate stenting strategy.

Patients and Methods

Study population

This multi centers, prospective trial targeted patients who presented with ST-segment elevation myocardial infarction (STEMI) and treated with primary PCI in Benha University Hospital and National Heart Institute in Cairo.

Inclusion criteria

- Patients with a high angiographic thrombus burden (thrombus burden score ≥ 3) [6].
- Patients who gained at least TIMI flow II or III spontaneously or after manual aspiration and/or balloon dilatation.

Study protocol

One hundred patients subjected either to immediate or deferred stenting strategies according to discretion of the operator. They were divided into two main groups based on the strategy of management:
**Group 1**: included 50 patients who were treated with conventional immediate stenting.

**Group 2**: included 50 patients who were treated with deferred stenting.

The study was explained to all participants and/or their relatives and informed consent was taken from all subjects of the study before starting the study. Approval of the ethical committee of (Benha faculty of medicine) according to declaration of Helsinki for ethical principles of medical research involving human subjects was obtained.

**Methods**

**Full medical history, clinical examination and ECG**

Age and gender, risk factors as diabetes, hypertension and smoking were defined according to recent guidelines [7]. History of prior angina, PCI or CAGB was documented. Detailed clinical examination with concern to patient’s Killip class on admission with standard twelve lead ECG aimed to establish the diagnosis, guide the therapy and to monitor arrhythmias.

**Laboratory investigation**

Kidney function tests, complete blood count, prothrombin time, concentration and international normalized ratio (INR) on admission. Cardiac enzymes (CK-MB and cardiac troponin) tested on admission and after intervention.

**Echocardiography assessment**

Using VIVID S5, GE machine, before and within hospital stay with emphasis on: LV end diastolic and end systolic dimensions, Left ventricular ejection fraction EF% (by Simpson method) or presence of mechanical complication.

**Percutaneous coronary intervention**

Coronaries were accessed through femoral or radial artery, according to the operator decision. Variety of supporting guiding catheters and floppy wires were used according to the feasibility, suspected culprit vessel and sometimes to the operator decision. The patients who had intracoronary thrombi with TIMI flow II or less subjected to wire introduction, thrombus aspiration using suction device and/or dilation of the lesion with an undersized balloon to achieves at least TIMI flow II.

**Study endpoints**

Procedural angiographic events were the primary endpoints, while in hospital major adverse cardiovascular events or bleeding complications were designed as secondary endpoints.

**Primary end points**

The angiographic complications defined as follow:

- Distal embolization as the presence of filling defects in or cut-off of a distal branch.
- Slow flow as TIMI grade 2 flow at the end of the procedure.
- No reflow as TIMI grade 1 or 0 flow in the distal infarct-related artery in the absence of an occlusion at the treatment site or evidence of distal embolization [8].

**Secondary end points**

Composite endpoint of cardiac mortality, non-fatal myocardial infarction and/or target vessel revascularization (TVR) was reported [9]. Hemodynamic instability as cardiogenic shock or pulmonary edema was considered. Urgent revascularization in the form of PCI to infarct related artery (IRA) was assessed.

Bleeding complications were defined according to Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries (GUSTO) score into: Severe or life-threatening, moderate or mild bleeding [10].

**Statistical analysis**

The association between variables and treatment groups was investigated by Mann Whitney U and Chi-square tests. A p value less than 0.05 were considered significant (2-sided). All analyses were carried out using Stata 12 software (StataCorp LP, College Station, Texas).

**Results**

**Demographic, clinical and echocardiographic data**

Male gender represented (74%) of the study populations with mean age of 57 years. The baseline demographic, clinical and echocardiographic characteristics were matched with non-significant differences between both groups. All data were demonstrated in table 1.

**Angiographic data**

Femoral approach was the common access for coronary

---

**Table 1: Comparison between two groups regarding the demographic, clinical and echocardiographic data.**

<table>
<thead>
<tr>
<th></th>
<th>Group 1</th>
<th>Group 2</th>
<th>Test</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age ± SD</td>
<td>57.5 ± 10.3</td>
<td>56.5 ± 11.1</td>
<td>0.435</td>
<td>0.664</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>60 (33 – 72)</td>
<td>58 (36 – 75)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>36 (72%)</td>
<td>38 (76%)</td>
<td>0.208‡</td>
<td>0.648</td>
</tr>
<tr>
<td>Female</td>
<td>14 (28%)</td>
<td>12 (24%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>30 (60%)</td>
<td>27 (54%)</td>
<td>0.367‡</td>
<td>0.545</td>
</tr>
<tr>
<td>Diabetes</td>
<td>25 (50%)</td>
<td>24 (48%)</td>
<td>0.040‡</td>
<td>0.841</td>
</tr>
<tr>
<td>Smoking</td>
<td>22 (44%)</td>
<td>24 (48%)</td>
<td>0.161‡</td>
<td>0.688</td>
</tr>
<tr>
<td>Prior angina</td>
<td>12 (24%)</td>
<td>15 (30%)</td>
<td>0.457‡</td>
<td>0.499</td>
</tr>
<tr>
<td>Killip Class I</td>
<td>23 (46%)</td>
<td>25 (50%)</td>
<td>0.843‡</td>
<td>0.839</td>
</tr>
<tr>
<td>Class II</td>
<td>14 (28%)</td>
<td>15 (30%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class III</td>
<td>9 (18%)</td>
<td>8 (16%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class IV</td>
<td>4 (8%)</td>
<td>2 (4%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total ischemic time (h) Mean ± SD</td>
<td>5.7 ± 2.4</td>
<td>5.9 ± 2.6</td>
<td>-0.306*</td>
<td>0.760</td>
</tr>
<tr>
<td>LVEF (%) Mean ± SD</td>
<td>47.8 ± 7.4</td>
<td>48.6 ± 6.5</td>
<td>-0.719*</td>
<td>0.472</td>
</tr>
</tbody>
</table>

* Mann Whitney U test. ‡ Chi-square test.
angiography; radial approach is achieved in (16% and 14%) in group 1 and group 2 respectively. LAD represented as the IRA in group 1 and group 2 (50% and 52%) respectively, followed by RCA in (32% and 26%) then LCX in (18% and 22%). Only culprit lesions were done for all patients including patients with cardiogenic shock according to ESC guidelines for coronary revascularization in 2018 [11]. Initial TIMI flow (at initial angiography) was comparable in both groups; (P value = 0.874), the same as thrombus burden score that was nearly equal in both groups; (P value = 0.072) (Table 2). Culprit residual lesion length and culprit residual stenosis was comparable after initial thrombectomy procedure (P value = 0.49 & 0.91) (Table 2).

Tirofiban (25 μg/kg bolus followed by 0.15 μg/kg/min maintenance) or eptifibatide (180 μg/kg bolus, infusion 2 μg/kg/min) was administered intravenously immediately after initial PCI in all patients with deferred stenting and maintained for 20–48 hours, renal adjusted doses were used in patients with renal impairment. Only patients with major thrombotic complications (no or slow flow or significant distal embolization) in immediate stenting group were received GP IIb IIIa inhibitors (8 patients; 16% for a mean duration of 24h). Coronary angiography in the delayed stenting group was performed 24 to 48h after initial angiography with mean duration of 36h. Stenting was needed less frequently in the deferred stenting group. 12 patients had no longer significant coronary stenosis at the time of the delayed procedure and this was statistically significant (P value < 0.001).

Primary endpoints (angiographic outcomes): Among patients of deferred stenting group no any cases of no reflow recorded, while 7 cases occurred in immediate stenting group (14%) (P value = 0.016).

Among patients of immediate stenting group, TIMI III flow was achieved in 41 patients (82%), while composite of slow flow and no reflow occurred in 9 cases (18%) (Table 3). However, the rate of patients achieving TIMI grade III flow at the end of PCI procedure was higher in the deferred stenting group compared with immediate stenting group; this was statistically non-significant (94% and 82.0%) (P value = 0.065) (Table 3). Distal embolization occurred more frequently in immediate stenting group, 7 patients (14%) (Five had small distal filling defect and two had abrupt cut off distally) versus 5 patients (10%) in the deferred stenting group (four had just small filling defect distally in the infarct related vessel, one had abrupt cut off distally) (P value = 0.538) (Table 3).

Secondary endpoints (clinical outcome): Major adverse cardiac events were observed in the two groups during the initial hospital stay that was ranged from two to five days. The composite of MACES was statistically significant in the deferred stenting group (20%) versus only (6%) in the immediate stenting group (P value = 0.037) (Table 4).

Regarding cardiac mortality, One patient died in immediate stenting group secondary to cardiogenic shock while 5 patients died in deferred stenting group (2 after cardiogenic shock and 3 with sudden cardiac death), this was statistically non significant (P value = 0.12) (Table 4). Due to recurrence of symptoms within 48 hours after the procedure, target vessel revascularization (TVR) was needed for only one patient in the immediate stenting group while was needed for 3 patients in deferred stenting group (P value = 0.85) (Table 4). One patient complicated with re-infarction in the immediate stenting group versus 2 patients in the deferred stenting group (P value = 0.56). Enhanced antithrombotic therapies showed no increase in major or moderate bleeding in the deferred stenting group compared with the immediate stenting group, Minor hemorrhagic complications were observed in 3 patients (6%) in deferred stenting group versus 2 patients (4%) in immediate stenting group (P value = 0.64) (Table 4).

Discussion

Percutaneous coronary intervention (PCI) has emerged as the strategy of choice for re-establishing effective flow in occluded IRA in patients with STEMI [12]. While immediate PCI is often the preferred strategy in this situation, distal embolization is still observed in large percentage of patients after primary PCI, and is associated with incomplete ST segment resolution, increased necrosis volume and poor outcome with increase in 5-year mortality [13]. Delaying or deferred stenting in primary PCI has been investigated as an option to reduce microvascular obstruction and preserve microcirculatory function in two small trials with conflicting results [14]. In current study, TIMI III flow was achieved in majority of deferred stenting group (94%) versus only (82%) in immediate stenting group (P value = 0.065) (Table 3). The thrombus related angiographic complications as no reflow were completely absent in deferred stenting group (0%) while detected in seven patients of immediate stent group (14%) (P value = 0.016) (Table 3). Distal embolization was occurred less frequently in deferred stenting group (10% versus 14%) (P value = 0.53) (Table 3). Current study showed better angiographic outcomes for deferred stenting strategy. In comparable to these results, the incidence of no or slow flow varies in different studies in patients directly revascularized for acute myocardial infarction from 12–30%. Tang et al in 2011 showed that stent implantation appears to further increase the risk of no reflow in patients undergoing primary PCI [15]. During acute phase of STEMI, the release of vasoconstrictive substances from platelets may explain the reduction in TIMI flow during stent deployment at high-pressure balloon inflation so postponed stenting allows both spontaneous structural modifications and pharmacological treatment to act with time on the platelet thrombus and fibrin rich clot, resulting in enhancement of clot lysis and dissolution of thrombus and so less distal embolization. Meanwhile, deferred PCI was therefore protectively associated against these complications. In addition, the deferred stenting approach may avoid unnecessary stent implantation. In current study, stenting was less frequently needed in the deferred stenting group. 12 patients had no longer significant coronary stenosis at the time of the delayed procedure and this was statistically significant; (P value <0.001). In correlation with current study, Cafrì et al in 2004 concluded that stent implantation is avoided in (22.6%) patients underwent delayed PCI [16]. In addition, deferred stenting was associated with slightly shorter stent length (26.00 ± 7.49 versus 26.04 ± 7.62) (P value = 0.993). This could be explained with spontaneous and pharmacological-induced angiographic changes of the vessel and lesion within time. Shorter stents that can be implanted secondarily after first delay could have lower rates of long-term restenosis than longer stents implanted in emergency.

As the results of angiographic outcomes, it was believed that deferred stenting would provide some clinical potential advantages that could reduce MACEs in comparison to immediate stenting. The above-mentioned angiographic advantages were not translated into significant clinical benefit in current study. MACEs were observed in the two groups during the initial hospital stay and also observed during the period between initial coronary angiogram and deferred PCI.

Composite of cardiac mortality, TVR and re-infarction showed statistically significant decrease in immediate stenting group (6% versus 20%) (P value = 0.037) (Table 4). TVR was needed in only one patient in the immediate stenting group while TVR was needed in three patients in deferred stenting group within 48 hours after the initial procedure. Documented re-infarction occurred in only one patient of immediate stenting group while 2 patients had re-infarction in deferred stenting group. Previously, the results of Meneveau et al. in 2009 showed no statistically significant differences in terms of MACEs between delayed or immediate stenting strategies (P value = 0.64) [17]. More recently, in the larger deferred versus conventional stent implantation trial (The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: DEFErred stent implantation in connection with primary PCI (DANAMI 3-DEFER)). 1215 STEMI patients were included; there was no effect on the primary clinical outcome (composite of death, non-fatal MI, or ischaemia-driven revascularization of non-IRA lesions) over a median follow-up of 42 months between the two strategies [18]. As regard bleeding complications , no increase in major or moderate bleeding in the deferred stenting group compared with the immediate stenting group, Minor hemorrhagic complications were observed in (6%) of deferred stenting group versus (4%) in immediate stenting group (P value =1.0) (Table 4). In agreement, there was no more major bleeding complication noted in the study of Tang et al. [19].

Conclusion

Deferred stenting in patients with STEMI especially those with high thrombotic burden improves the angiographic outcomes but could not improve the short term clinical outcomes in comparison to immediate stenting. Deferred stenting shouldn’t be a routine strategy in STEMI patients. Further evaluation in adequately powered trials with larger number of patients and longer follow up duration are awaited to confirm the clinical benefit of this strategy in this group of population.

References


on myocardial revascularization, Eur Heart Journal 1-96. Link: https://goo.gl/1JzTTf


